$3.2 Billion is the total value of Redmile Group, LLC's 70 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KYMR | Buy | KYMERA THERAPEUTICS INC | $110,668,000 | -32.6% | 2,615,030 | +1.1% | 3.46% | -7.5% |
| SKIN | Buy | THE BEAUTY HEALTH COMPANY | $89,540,000 | -27.1% | 5,304,505 | +4.4% | 2.80% | +0.1% |
| RGNX | Buy | REGENXBIO INC | $65,614,000 | +5.8% | 1,976,923 | +4.2% | 2.05% | +45.2% |
| SGEN | Buy | SEAGEN INC | $63,566,000 | +10.6% | 441,274 | +18.7% | 1.98% | +51.8% |
| CNC | Buy | CENTENE CORP DEL | $54,626,000 | +83.6% | 648,837 | +79.7% | 1.70% | +151.8% |
| IMGN | Buy | IMMUNOGEN INC | $43,877,000 | -28.4% | 9,217,945 | +11.6% | 1.37% | -1.7% |
| NRIX | Buy | NURIX THERAPEUTICS INC | $42,293,000 | -50.6% | 3,018,784 | +2.0% | 1.32% | -32.2% |
| VERV | Buy | VERVE THERAPEUTICS INC | $41,882,000 | -33.5% | 1,835,328 | +7.4% | 1.31% | -8.7% |
| ONEM | New | 1LIFE HEALTHCARE INC | $37,726,000 | – | 3,404,835 | +100.0% | 1.18% | – |
| TNDM | New | TANDEM DIABETES CARE INC | $31,540,000 | – | 271,218 | +100.0% | 0.98% | – |
| NVRO | Buy | NEVRO CORP | $29,729,000 | +35.8% | 411,017 | +52.2% | 0.93% | +86.3% |
| GRTS | Buy | GRITSTONE BIO INC | $28,312,000 | -35.8% | 6,871,738 | +100.4% | 0.88% | -11.9% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $17,865,000 | +43.0% | 114,764 | +17.0% | 0.56% | +96.5% |
| RAPT | New | RAPT THERAPEUTICS INC | $16,463,000 | – | 748,677 | +100.0% | 0.51% | – |
| ALLK | Buy | ALLAKOS INC | $14,592,000 | -28.3% | 2,559,975 | +23.2% | 0.46% | -1.3% |
| ZYME | Buy | ZYMEWORKS INC | $13,848,000 | -3.4% | 2,114,197 | +141.8% | 0.43% | +32.5% |
| HOOK | Buy | HOOKIPA PHARMA INC | $10,572,000 | +90.2% | 4,636,648 | +94.4% | 0.33% | +161.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.